- Current report filing (8-K)

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 10, 2012

Date of Report (Date of earliest event reported)

IMMUNOTECH LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Nevada		333-57514		95-4834274
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification Number)

116 West Stocker Street, Glendale, California		91202
(Address of principal executive offices)		(Zip Code)

[phone]

Registrant’s telephone number, including area code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

[  ]		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 5.02.  Appointment of Certain Officers.

 

On October 10, 2012 Immunotech Laboratories signed a contract with Mr. Bo Linton and appointed him to be part of the Board of Directors.

 

 

Item 9.01                    Financial Statements and Exhibits

 
 

Exhibit

Number               Description

 
 

99.1                      Press Release

 

---

 

SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		IMMUNOTECH LABORATORIES, INC.
Date: October 10, 2012	By:	/s/ Harry Zhabilov
		Harry Zhabilov
		President